POTENTIATION OF PHARMACOLOGICAL AND THERAPEUTIC ACTION OF PHENOTHIAZINES BY NYLIDRIN (ARLIDIN).
D001714:Bipolar Disorder; D001921:Brain; D001925:Brain Damage, Chronic; D002749:Chlorprothixene; D003865:Major Depressive Disorder; D003911:Dextrans; D005853:Geriatrics; D006220:Haloperidol; D006801:Humans; D008728:Methotrimeprazine; D009756:Nylidrin; D010640:Phenothiazines; D011600:Psychopharmacology; D011618:Psychotic Disorders; D051381:Rats; D012106:Research; D012559:Schizophrenia; D014665:Vasodilator Agents
D003911:Dextrans; D010640:Phenothiazines; D014665:Vasodilator Agents; D009756:Nylidrin; D008728:Methotrimeprazine; D002749:Chlorprothixene; C031637:phenothiazine; D006220:Haloperidol
BRAIN DAMAGE, CHRONIC; CHLORPROTHIXENE; DEXTRAN; EXPERIMENTAL LAB STUDY; GERIATRICS; HALOPERIDOL; METHOTRIMEPRAZINE; PHENOTHIAZINES; PSYCHOPHARMACOLOGY; PSYCHOSES, INVOLUTIONAL; PSYCHOSES, MANIC-DEPRESSIVE; RATS; SCHIZOPHRENIA; VASODILATOR AGENTS